InvestSMART

Cytokinetics (NASDAQ: CYTK) - Share Price

Current share price for CYTK : $74.100 0.65 (0.88%)+

Currency: USD ($)

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

CYTK General Information +

NASDAQ Code CYTK
Industry/Sector Biotechnology
Market Cap ($M) 9,220
CYTK Share Price $74.100
Day High $74.240
Day Low $72.160
Last Close $73.450
CYTK Share Price Movement $0.65 ( 0.88% )
Prices as at 3:36, 15 Aug 2026
+Security prices are at best end-of-day and are indicative only.

CYTK Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
$0.06 $1,318.72 ($15.89) n/a n/a n/a -8.32

CYTK Calendar of Events

Created Date Changed Date Event
10 April 2025 11 April 2025 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.